Jan 31, 2026
How do GLP‑1 agonists compare with SGLT2 inhibitors for cardiovascular outcomes in type 2 diabetes?
Large randomized trials and multiple meta-analyses show that both GLP‑1 receptor agonists and SGLT2 inhibitors meaningfully reduce major adverse cardiovascular events (MACE) in people with type 2 diab...